...

CCO Independent Conference Coverage

2008 San Antonio Breast Cancer Symposium*

December 10-14, 2008 | San Antonio, Texas

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Early Breast Cancer

Track 1 of 3

Moderator: Robert S. Mocharnuk, MD

Faculty:

Harold J. Burstein, MD, PhDPeter Ravdin, MD, PhDHope S. Rugo, MD
  • Harold J. Burstein, MD, PhD
  • Peter Ravdin, MD, PhD
  • Hope S. Rugo, MD

Metastatic Breast Cancer

Track 2 of 3

Moderator: Richard Finn, MD

Faculty:

Clifford A. Hudis, MDKathy D. Miller, MDJoyce O’Shaughnessy, MD
  • Clifford A. Hudis, MD
  • Kathy D. Miller, MD
  • Joyce O’Shaughnessy, MD

Prediction and Prognosis

Track 3 of 3

Moderator: Jeffrey B. Smerage, MD, PhD

Faculty:

Matthew Ellis, MD, PhDWilliam J. Gradishar, MD, FACPEdith A. Perez, MD
  • Matthew Ellis, MD, PhD
  • William J. Gradishar, MD, FACP
  • Edith A. Perez, MD

CCO Slideset

Breast Cancer: Highlights CCO Independent Conference Coverage of the 2008 San Antonio Breast Cancer Symposium

Download the Slideset


Downloadable slideset highlighting some of the most significant data presented in the adjuvant and metastatic settings as well as studies focused on predictive and prognostic factors.


Format: Microsoft PowerPoint (.ppt) | File size: 3.41 MB | Date posted: 1/22/2009


Expert Highlights

William J. Gradishar, MD, FACP headshot William J. Gradishar, MD, FACP, discusses key studies presented on molecular markers and tools for predicting treatment benefit in breast cancer patients. (9 minutes) Download Audio
Kathy D. Miller, MD headshot Kathy D. Miller, MD, reviews the top studies presented for the treatment of metastatic breast cancer including the use of mTOR inhibitors, HDAC inhibitors, antiangiogenic agents, and hormonal therapies. (10 minutes) Download Audio
Hope S. Rugo, MD headshot Hope S. Rugo, MD, discusses the highlights of presentations on early breast cancer, including hormone therapy, HER2-directed therapy, use of bisphosphonates to prevent bone loss, and adjuvant therapy. (12 Minutes) Download Audio

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.

Capsule Summary:

Temsirolimus Monotherapy Shows Minimal Activity in Heavily Pretreated Patients With Metastatic Breast Cancer

No correlation observed between PIK3CA mutations and sensitivity to temsirolimus in heavily pretreated metastatic breast cancer patients.

CLICK HERE TO KEEP READING

CLICK HERE FOR RELATED CAPSULE SUMMARIES